Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy
- PMID: 19091330
- DOI: 10.1016/j.jns.2008.11.015
Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy
Abstract
To develop diagnostic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP), a retrospective series of patients' records diagnosed by sexpert consensus as CIDP or other chronic polyneuropathies were analyzed. Classification and regression tree analysis was applied to 150 patients to derive a classification rule. According to the rule, diagnosis of CIDP required that a patient have a chronic non-genetic polyneuropathy, progressive for at least eight weeks, without a serum paraprotein and either 1) recordable compound muscle action potentials in > or =75% of motor nerves and either abnormal distal latency in >50% of nerves or abnormal motor conduction velocity in >50% of nerves or abnormal F wave latency in >50% of nerves; or 2) symmetrical onset of motor symptoms, symmetrical weakness of four limbs, and proximal weakness in > or =1 limb. When validated in 117 patients, the rule had 83% sensitivity (95% confidence interval 69%-93%) and 97% specificity (95% confidence interval 89%-99%) and performed better than published criteria.
Similar articles
-
Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37 degrees C: diagnostic yield in chronic inflammatory demyelinating polyneuropathy.Brain. 2005 Apr;128(Pt 4):880-91. doi: 10.1093/brain/awh375. Epub 2005 Feb 2. Brain. 2005. PMID: 15689367
-
Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.Arch Neurol. 2003 Dec;60(12):1755-9. doi: 10.1001/archneur.60.12.1755. Arch Neurol. 2003. PMID: 14676052
-
Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases.J Peripher Nerv Syst. 2005 Sep;10(3):282-92. doi: 10.1111/j.1085-9489.2005.10306.x. J Peripher Nerv Syst. 2005. PMID: 16221287 Clinical Trial.
-
Management strategies in chronic inflammatory demyelinating polyradiculoneuropathy.Neurol India. 2010 May-Jun;58(3):351-60. doi: 10.4103/0028-3886.65534. Neurol India. 2010. PMID: 20644261 Review.
-
Chronic inflammatory demyelinating polyneuropathy: a treatment protocol proposal.Expert Rev Neurother. 2006 Mar;6(3):365-79. doi: 10.1586/14737175.6.3.365. Expert Rev Neurother. 2006. PMID: 16533141 Review.
Cited by
-
Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.Front Immunol. 2019 Mar 21;10:515. doi: 10.3389/fimmu.2019.00515. eCollection 2019. Front Immunol. 2019. PMID: 30984164 Free PMC article.
-
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.Cochrane Database Syst Rev. 2017 May 8;5(5):CD003280. doi: 10.1002/14651858.CD003280.pub5. Cochrane Database Syst Rev. 2017. PMID: 28481421 Free PMC article.
-
Immune-Mediated Neuropathies: Pathophysiology and Management.Int J Mol Sci. 2023 Apr 14;24(8):7288. doi: 10.3390/ijms24087288. Int J Mol Sci. 2023. PMID: 37108447 Free PMC article. Review.
-
Chronic inflammatory demyelinating polyneuropathy.Curr Treat Options Neurol. 2013 Jun;15(3):350-66. doi: 10.1007/s11940-013-0229-6. Curr Treat Options Neurol. 2013. PMID: 23564314 Free PMC article.
-
An update on the management of chronic inflammatory demyelinating polyneuropathy.Ther Adv Neurol Disord. 2012 Nov;5(6):359-73. doi: 10.1177/1756285612457215. Ther Adv Neurol Disord. 2012. PMID: 23139706 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources